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Abstract 
 
The Microbiome as a Mediator of Type 2 Diabetes Mellitus in Mexican 
Americans 
 
Amanda Kristine Kitten, MSPS 
The University of Texas at Austin, 2019 
 
Supervisor:  Kelly R Reveles 
 
Type 2 diabetes mellitus (T2DM) is an urgent public health problem and 
disproportionately affects Mexican-Americans. The gut microbiome contributes to the 
pathophysiology of diabetes; however, no studies have examined this association in 
Mexican-Americans. The objective of this study was to compare gut microbiome 
composition between Mexican-Americans with and without T2DM. 
This was a cross-sectional study of volunteers from San Antonio, TX. Subjects 
were 18 years or older and self-identified as Mexican-American. Subjects were grouped 
by T2DM diagnosis. Eligible subjects attended a clinic visit to provide demographic and 
medical information. Thereafter, subjects recorded what they ate for three days and 
collected a stool sample on the fourth day. Stool 16s rRNA sequences were classified into 
operational taxonomic units (OTUs) via Mothur’s Bayesian classifier and referenced to the 
Greengenes database. Alpha diversity and taxa relative abundance were compared between 
groups using the Wilcoxon rank sum test. Beta diversity was estimated using Bray-Curtis 
indices and compared between groups using PERMANOVA. 
 vii 
Thirty-seven subjects were included, 14 (38%) with diabetes and 23 (62%) without 
diabetes. Groups were well-matched by body mass index (BMI) (diabetes 30 mg/kg2, no 
diabetes 28 mg/kg2; p=0.4653) and other comorbid conditions. Alpha diversity was not 
significantly different between those with and without T2DM (3.21 vs. 3.07; p=0.3409). 
Beta diversity was not significantly associated with T2DM diagnosis (p=0.1249). Sixteen 
operational taxonomic units (OTUs) were significantly different between groups. There 
was a significantly lower relative abundance (RA) of Streptococcus in those with T2DM 
(p=0.04). The Firmicutes to Bacteroidetes ratio was higher in those with T2DM (0.637:1) 
compared to those without T2DM (0.507:1).  
In conclusion, although alpha diversity was not different between diabetic and non-
diabetic Mexican-Americans, the microbial composition was significantly different.   
 viii 
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Chapter One:  Role of the Microbiome in Human Health  
OVERVIEW OF THE HUMAN MICROBIOME 
The human microbiome is an expanding area of clinical research. Scientific 
literature examining the role of the microbiome in human health has expanded substantially 
over the last ten years.1 This has led to the identification of the microbiome as a major 
contributor to human health and disease.2 The microbiome refers to the collection of all 
genomes of microbes in an ecosystem. On the other hand, microbiota describes the 
microbes, including bacteria, archea, viruses, and fungi, that collectively inhabit a given 
ecosystem.3 Dysbiosis occurs when there is a disturbance or change in the composition and 
function of these microbes. Many studies focus specifically on the bacterial component of 
the gut microbiota, as bacteria contribute the greatest amount of genetic material 
(approximately 99.1%, compared to 0.1% of genetic material from eukaryotic and viral 
sources).4 The impact of the human microbiome on health is not surprising considering its 
scope; the number of bacterial cells outnumber human cells at a ratio of 10:1.5 Of the vast 
number of bacterial cells in and on the human body, 95% are located in the gastrointestinal 
tract.  
Several tools exist for the purposes of analyzing the contents of the microbiome 
(Figure 1). Different tools can be used to identify community composition, gene 
expression, protein expression, and metabolic activity.6 The most common approach is 16S 
rRNA gene sequencing which utilizes 16S rRNA amplification with polymerase chain 
reaction (PCR). These genes are then sequenced using next-generation sequencing 
technology. Machine learning is then used to cluster similar sequences, and reference 
databases, such as Greengenes, assist with assigning taxonomy. 
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Figure 1: Gut Microbiome Analysis (adapted from Ishiguro and Campbel 2018)7 
 
The composition of the human microbiome varies by body site. Outer body sites 
are predominated by Gram-positive aerobic organisms from the Actinobacteria and 
Firmicutes phyla.8 The gut microbiome is predominated by anaerobic Gram-positive and 
Gram-negative bacteria, including the phyla Firmicutes, Bacteroidetes, and Actinobacteria. 
Most variation in the microbiota occurs at progressively lower taxonomic levels, with high 
conservation at the highest levels.8  
Several measures exist to aid in comparing the gut microbiomes of different groups. 
First, alpha diversity measures the quantity of different bacterial taxa, or richness,  within 
a bacterial community.9 High alpha diversity indicates a high quantity of different bacteria. 
Shannon diversity, a type of alpha diversity, accounts for both richness and evenness, 
where evenness refers to the degree of similarity in the proportional abundance between 
different bacterial taxa. Beta diversity refers to differences in diversity between subjects. 
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Beta diversity is visually represented using a principle coordinate analysis (PCoA). To 
produce a PCoA, each bacterial community is assigned two coordinates based on 
compositional diversity. Each community is then plotted on a diagram where distance 
between points represents the overall difference between the communities.  
 
GLOBAL GUT MICROBIOTA FUNCTIONS 
The gut microbiome carries out several important functions. It helps to train the 
immune system and inhibits invasion by pathogens, such as Clostridioides difficile.3,10  The 
gut microbiota also mediates host-cell proliferation and vascularization and regulates 
multiple signaling molecules that control endocrine and neurologic function.3 Gut bacteria 
also provide a source of energy biosynthesis. Additionally, they synthesize vitamins, 
neurotransmitters, and other related compounds. Other important roles include metabolism 
of bile salts and xenobiotic metabolism and elimination.  
 
ASSOCIATIONS BETWEEN GUT DYSBIOSIS AND HUMAN DISEASE 
Given the many functions of the gut microbiome, it is no surprise that an association 
exists between gut dysbiosis and human disease.2 Multiple factors influence the 
composition of the gut microbiome, those which are not modifiable, including neonatal 
mode of delivery, host genetic features, host immune response, and age, as well as those 
that are modifiable: diet, medications, environmental exposures, physical activity, 
smoking, and alcohol consumption.3 An imbalance in the gut community can cause a shift 
from a healthy metabolic condition to one that predisposes an individual to disease 
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development including diabetes, obesity, metabolic syndrome, cancer, inflammatory bowel 
disease (IBD), irritable bowel syndrome (IBS), and cardiovascular disease (Table 1).  
 
Table 1: Influence of the Gut Microbiome on Health 
Health Microbial products or activities Disease 
Nutrient & 
energy supply 
• SCFA production & vitamin synthesis 
• Energy supply, gut hormones, & satiety 
• Lipopolysaccharides, inflammation 
Obesity & 
metabolic 
syndrome 
Cancer 
prevention 
• Butyrate production, phytochemical release 
• Toxin and carcinogen inflammation 
• Mediates inflammation 
Cancer promotion 
Pathogen 
inhibition 
• SCFA production, intestinal pH, 
bacteriocins 
• Competition for substrates and/or binding 
sites 
• Toxin production, tissue invasion, 
inflammation 
Pathogen invasion 
GI immune 
function 
• Balance of pro- and anti-inflammatory 
signals 
• Inflammation, immune disorders 
IBD 
Gut motility • Metabolites (SCFAs, gases) from non-
digestible carbohydrates 
IBS (constipation, 
diarrhea, bloating) 
Cardiovascular 
health 
• Lipid & cholesterol metabolism Cardiovascular 
disease 
GI, gastrointestinal; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome 
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Chapter Two: Gut Dysbiosis and Diabetes Mellitus 
OVERVIEW OF DIABETES MELLITUS 
As of 2015, 30.3 million Americans, or 9.4% of the population, had diabetes 
mellitus (DM).11 Approximately one-third were undiagnosed. The majority of those with 
diabetes (approximately 29 million of the 30.3 million have T2DM). Diabetes represents a 
substantial burden and is associated with significant morbidity and mortality.12,13 In 2017, 
diabetes and its complications, including cardiovascular disease, retinopathy, nephropathy, 
and neuropathy, resulted in an annual cost of $237 billion in direct medical costs and $90 
billion in reduced productivity.11 In 2015 diabetes was the seventh leading cause of death 
in the United States. 
 
PATHOPHYSIOLOGY: THE EGREGIOUS ELEVEN 
Healthcare providers’ understanding of diabetes has evolved over time. Although 
diabetes was initially understood as a disorder of the pancreas, researchers have now 
identified 11 dysfunctional pathways that contribute to the development of diabetes (Figure 
2).14,15  
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Figure 2: Beta-cell-centric Construct: Egregious Eleven (adapted from Schwartz, et al 
2016)15 
 
All 11 pathways contribute to diabetes pathophysiology by either negatively 
affecting beta-cell function or further potentiating hyperglycemia.15 The most recently 
identified pathways include immune dysregulation, increased glucose absorption from the 
gastrointestinal tract, and changes in the gut microbiome composition.  
Studies of the gut microbiome have identified major mechanisms through which it 
can influence energy homeostasis and contribute to diabetes (Figure 3).16 
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Figure 3: Microbiome and Host Metabolism (adapted from Allin, et al, 2015)16 
 
First, high levels of lipopolysaccharides (LPS) exert detrimental effects on glucose 
homeostasis. Gram-negative bacteria shed LPS from their cell walls.17,18 LPS bind to the 
toll-like receptor-4 (TLR4)/CD12 complex, which activates the innate immune system. 
Additionally, LPS decrease the expression of tight junction proteins. The resultant decrease 
in the integrity of the gut mucosa allows for translocation of LPS and intestinal microbes 
into the bloodstream. Studies have demonstrated that subjects with DM have higher plasma 
levels of LPS compared to their healthy counterparts.18 Increased LPS levels lead to further 
systemic inflammation, immune cell invasion of liver and adipose tissue, and ensuing 
insulin resistance in these tissues.16 
high-fat diet (21) and mice receiving antibiotics exhibited
lower levels of circulating LPSs and TNFa as well as
decreased insulin resistance compared wit p ir-fed mice
(22). As a part of the immune system, Toll-like receptors
(TLRs) recognise microbial molecules a d activate the
innate immune system. LPSs bind to and activate the
TLR4/CD14 complex, which activates pro-inflammatory
pathways. Other TLRs, such as TLR2 and TLR5, have also
been proposed to be part of the signalling pathways
affecting the development of metabolic syndrome as
observed i studies of Tlr2- and Tlr5-deficient mice
(23, 24). Additional evidence of the importance of the
cr sstalk amo g the immune system, inflammation
and metabolism was observed in the development of
non-alcoholic fatty liver disease (NAFLD). Mice without
the inflammasome complexes NLRP3 or NLRP5,
A. Lipopolysaccharide B. Short-chain fatty acids
Dietary fibres Butyrate
Acetate
Propionate
C. Bile acids
Primary
bile acids
Secondary
bile acids
TLR4 Energy source
↑ Inflammation
↑ Lipogenesis
↑ Gluconeogenesis
↑ GLP1 and PYY
↓ Inflammation
GPR41 
GPR43
↑ GLP1↑ Energy expenditure
TGR5
LPS
Figure 1
Microbes and host metabolism. Microbes may influence host
metabolism through numerous mechanisms, of which three
important mechanisms are depicted. (A) Lipopolysaccharide.
Lipopolysaccharide (LPS) originates from the outer membrane
of Gram-negative bacteria and binds to Toll-like receptor 4
(TLR4), which activates pro-inflammatory signalling pathways
resulting in low-grade inflammation and thus decreased insulin
sensitivity. (B) Short-chain fatty acids. Bacteri in the colon
ferment dietary fibres to short-chain fatty acids (mainly
butyrate, acetate and propionate). Acetate and propionate are
used as substrates for gluconeogenesis and lipogenesis in the
liver, whereas but rate is an import nt energy substrate for
colonic mucosa cells. Moreover, short-chain fatty acids bind to
the G protein-coupled receptors GPR41 and GPR43 resulting in
various effects depending on the cellular types affected. In
immune cells, this signalling results in decreased inflammation
and in the enteroendocrine L-cells it results in increased GLP1
and PYY levels together leading to improved insulin sensitivity.
(C) Bile acids. Primary bile acids are produced by the liver and
recirculated to the liver from the gut. However, gut bacteria are
capable of deconjugating primary bile acids hindering their
reci culation. The primary deconjugated bile acids are further
metabolised by gut bacteria to secondary bile acids. Secondary
bile acids bind to the G protei -coupled receptor TGR5, which
results in increased energy expenditure in muscles and GLP1
secretio in the entero ndocrine L-cells, both of which lead
to improved insulin sensitivity.
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Short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate, on the 
other hand, have beneficial effects with respect to glucose metabolism.18 SCFAs are 
produced through bacterial fermentation of non-digestible polysaccharides and serve as the 
main energy source for the gut epithelium and bind G-protein coupled receptors (GPCRs). 
Binding of SCFAs to GPCRs 41 and 43 induces glucagon-like peptide 1 (GLP-1) secretion 
which suppresses appetite, slows digestion, and increases insulin sensitivity. Additionally, 
GPCR binding inhibits inflammatory signaling molecules NF-kappa-B,  tumor necrosis 
factor-alpha, and interleukin-6, with an overall effect of decreasing inflammation. In 
diabetes-associated gut dysbiosis, there is a relative deficiency of bacteria that produce 
SCFAs.4,19,20 
Finally, in diabetes there is a relative deficiency of bacteria that produce bile salt 
hydrolases.19,21-24 Bile salt hydrolases have the important role of converting primary bile 
acids to secondary bile acids. Secondary bile acids act as signaling molecules to induce 
GLP-1 secretion from small intestinal L-cells. Changes in the relative abundance (RA) of 
certain bacteria have been implicated in these major mechanisms (Table 2). 
 
Table 2: Bacteria Involved in Metabolism 
LPS Producing Bacteria  SCFA Producers Microbiota with bile salt 
hydrolases 
E. coli 
Salmonella 
Shigella 
Pseudomonas 
Neisseria 
H. influenza 
Bordetella pertussis 
Vibrio cholerae 
Roseburia sp. 
Faecalibacterium prausnitzii 
Eubacterium hallii 
Eubacterium rectale 
 
Lactobacillus 
Bifidobacterium 
Firmicutes 
Enterococcus 
Clostridium 
Bacteroides 
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Researchers have identified two phyla, Firmicutes and Bacteroidetes, as 
appreciable producers of SCFAs and LPSs, respectively.17,18,25,26 The Firmicutes to 
Bacteroidetes ratio, which allows for comparison of both phyla’s RA, has been positively 
associated with metabolic disorders, possibly due to the increased energy harvest due to 
high levels of SCFAs.27 
 
THE GUT MICROBIOME COMPOSITION IN PATIENTS WITH DIABETES 
Several studies comparing the gut microbiomes of subjects with and without 
diabetes have yielded varying results. The earliest microbiome studies, performed in 
BioBreeding rats, indicated a relationship between the microbiome and metabolic 
disease.28 Specifically, alpha diversity correlated positively with higher disease rates. Lack 
of gut microbial diversity has been implicated in type 1 diabetes29-31, Crohn’s disease32, 
colorectal cancer33, and multiple sclerosis.34  Surprisingly, only one of the human studies 
of the gut microbiome in T2DM reflected this association between lack of diversity and 
disease.24 In contrast, other studies have not demonstrated any relationship between 
microbial diversity and T2DM,19,22 and only one study identified inter-group differences 
in beta-diversity.22 
In addition to analyzing diversity, previous studies have evaluated the abundance 
of various bacterial taxa. Bacteria significantly depleted in subjects with T2DM include: 
Bifidobacterium genus22,23, Firmicutes phylum19,21, and Roseburia genus.4,19,20 The 
relationship between these microbes and metabolism have been described previously. In 
mice studies, an increase in gut Bifidobacterium attributable to prebiotic fiber ingestion 
resulted in improved glucose tolerance and decreases in inflammatory markers.35 A high 
RA of Firmicutes, especially in relation to Bacteroidetes RA, has been implicated in obesity 
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and high BMI.8 Interestingly, the Firmicutes phylum contains many SCFA-producing 
bacteria that confer metabolic benefits.18 Specifically, many Roseburia species, which are 
members of the Firmicutes phyla, are butyrate-producers. Additionally, fecal 
transplantation from lean donors to subjects with metabolic syndrome resulted in an 
increase in Roseburia RA, butyrate levels, and insulin sensitivity.36 
The bacterial taxon consistently shown to be enriched in T2DM is the Lactobacillus 
genus.4,19,20,22,23 Lactobacillus has been implicated in obesity and is thought to be an 
immune-modulating bacteria.37,38	
Studies have yielded conflicting results regarding the RA of Prevotella19,24, 
Bacteroides 22,24, and Clostridia19,24 in T2DM. These discordant findings are likely due to 
differences in study population characteristics, such as age, diet, host genotype, physical 
activity, and geographic location. Further studies investigating the gut microbiome 
composition and diabetes relationship are needed.  
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Table 3: Bacterial Taxa Differences in Previous Studies 
References Microbiota in subjects with T2DM 
Wu et al. (2010), Sedighi 
et al. (2017)  
• Lower RA of Bifidobacterium 
Larsen et al. (2010), 
Lambeth et al. (2015) 
• Lower RA of Firmicutes, also negatively correlated with PG 
values 
Larsen, et al. (2010), Qin 
et al. (2012), Karlsson et 
al. (2013) 
• Roseburia significantly depleted, negative (non-significant) 
correlation with plasma glucose (R=-0.53, p=0.06) 
Larsen et al. (2010), 
Zhang et al (2013) 
• Higher RA of Prevotella  
• Bacteroides-Prevotella to Clostridia ratio positively 
correlated with PG (R=0.38, p=0.03) 
Wu et al. (2017) • Lower RA of Prevotella (10.7% versus 58.8%; p<0.05) 
Zhang et al. (2013) • Lower Bacteroides RA 
Wu et al. • Higher Bacteroides RA 
Larsen et al (2010), Wu et 
al. (2010), Qin et al. 
(2012),  Karlsson et al. 
(2013), Sedighi et al. 
(2017) 
• Higher RA of several Lactobacillus species 
• Lactobacillus RA positively correlated with PG levels 
Larsen et al. (2010) • Lower RA of Clostridia 
Zhang et al. (2013) • Higher RA of Clostridia 
RA, relative abundance 
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Chapter Three: Objectives and Hypothesis 
KNOWLEDGE GAP 
Despite the aforementioned studies, there are still major gaps in knowledge. When 
broken down by race and ethnicity, the rate of diabetes in Hispanics is relatively high at 
12.1%, compared to 7.4% in non-Hispanic Whites.11 Causes of high T2DM prevalence in 
Hispanics include disparities in income, education, and access to healthcare, as well as 
genetic predisposition to obesity and insulin resistance.39 More recently identified is the 
potential role of the gut microbiome in T2DM risk in Hispanic Americans. Ross, et al. 
compared the gut microbial composition between Hispanics in South Texas and the Human 
Microbiome Project (HMP) and found significant taxonomical differences between the two 
groups.40 Notably, the differences seen between this Hispanic cohort, 87.3% of whom did 
not have T2DM, and the HMP were similar to the differences seen in previous studies that 
compared controls to subjects with T2DM.41 Given this information, further investigation 
of the gut microbiome as a potential predisposing factor for T2DM in the Hispanic 
population is needed. Additionally, no studies discuss how baseline characteristics other 
than T2DM status might have contributed to their findings regarding gut microbiome 
composition. There is a need for studies that examine not only gut microbiome 
composition, but also differences in baseline characteristics between groups. Finally, 
conflicting results regarding diversity necessitate further investigation of gut microbial 
diversity differences between groups with and without T2DM. 
The majority of the San Antonio, TX population is Hispanic, 90% of whom are of 
Mexican origin.42 Among Bexar County residents, Hispanics represent the highest risk 
population with a diabetes rate of 13.1%, compared to both African Americans (12%), and 
Caucasians (8%).43 Therefore, our research group is in an ideal position to be able to 
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examine the gut microbiomes of Mexican Americans with and without T2DM and address 
these gaps in knowledge. 
 
OBJECTIVE 1: 
The primary objective of this study was to compare the diversity of the gut 
microbiome between Mexican Americans with and without T2DM. 
 
Hypothesis 1 
Gut microbiome alpha diversity is significantly different between Mexican 
Americans with and without T2DM. 
 
OBJECTIVE 2:  
Evaluate gut microbiome compositional differences between Mexican Americans 
with and without T2DM. 
 
Hypothesis 2 
Gut microbiome composition is different between Mexican Americas with and 
without T2DM. 
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OBJECTIVE 3: 
Identify demographic and other patient characteristics associated with gut 
microbial diversity. 
 
Hypothesis 3 
Patient characteristics, including age and BMI, are associated with gut microbial 
diversity. 
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Chapter Four: Methods 
STUDY DESIGN 
This was a cross-sectional study of volunteers from San Antonio, TX  and 
surrounding areas from June 2017 to July 2018. This study was approved by the 
Institutional Review Board at UT Health San Antonio and funded by the Research to 
Advance Community Health (ReACH) Pilot Grant Program.  
Subjects were recruited using newspaper advertisements in the San Antonio 
Express-News, Southside Reporter, and Conexion. Flyers were also placed in the Medical 
Arts and Research Center (MARC) in the South Texas Medical Center.  
Those interested in participating called the research team, and a research team 
member pre-screened subjects using a detailed questionnaire designed to exclude patients 
taking certain medications and with certain disease states (Appendix). If participants 
successfully completed pre-screening, their contact information was given to the staff at 
the First Outpatient Research Unit (FORU) and the MARC to schedule their research visit. 
 
STUDY POPULATION 
Subjects were included if they were at least 18 years old and self-identified as 
Mexican American. Subjects were excluded if they had a history of prior gastrointestinal 
surgery altering the anatomy of the gastrointestinal tract or certain medication use. 
Medication use that warranted exclusion included (1) chronic daily use of any medications 
meant to alter gastrointestinal secretory or motor function (e.g., prokinetic agents, narcotic 
analgesics, laxatives, anticholinergics, anti-diarrheals) and (2) use of antibiotics, gastric-
acid suppressing medications, or probiotics in the previous two months. Subjects were 
divided into groups based on T2DM status. Subjects were considered to have T2DM if they 
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had been previously diagnosed with T2DM and were currently receiving active treatment 
for diabetes. An overview of the study design can be found in Figure 4. 
 
 
 
Figure 4: Overview of Study Design 
 
DATA COLLECTION 
Data collection was performed at the FORU at the MARC. Subjects attended a 
single visit where they filled out a demographic and health questionnaire. A list of data 
collected can be found in Table 4. Subjects were provided with a three-day food diary and 
stool sample collection kit. Subjects were instructed to fill out the food diary for the 
following three days and collect a stool sample on the fourth day to be sent back to our 
research team.  
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Table 4: Data Collected from Subjects 
Age 
Height 
Weight 
BMI 
Sex 
Highest level of education 
Approximate income 
Current employment status 
Tobacco use 
Alcohol use  
Comorbidities (see Appendix 
for full list) 
Other conditions 
Medications 
Time since T2DM diagnosis 
HbA1c 
FBG 
 
SAMPLE PROCESSING AND SEQUENCING 
Stool samples were stored at -80 degrees C until sequencing. Microbiome Insights 
performed DNA extraction, sequencing, and analysis for our study. DNA was extracted 
from specimens using MoBIO PowerMag Soil DNA Isolation Bead Plate and 
KingFisher™ robot.  
Bacterial 16S rRNA genes were PCR-amplified using primers targeting the V4 
region. Primers were comprised of Illumina adapters, an 8-nucleotide index sequence, a 
10-nucleotide pad sequence to prevent hairpin formation, and a gene-specific primer. 
Amplicons were sequenced using the Illumina MiSeq 300-bp paired-end kit (v.3).  
Taxonomical classifications were denoised, taxonomically classified using the 
Greengenes v. 13_8 database, and clustered into 97%-similarity operational taxonomic 
units (OTUs) using Mothur Software package (v. 1.39.5).  
 
HEI SCORE CALCULATIONS 
HEI scores were calculated using subjects’ three-day food diaries. Total calorie 
intake was estimated using the United States Department of Agriculture Food Composition 
Databases.44 We assigned points based on the HEI-2015 scoring system, which is the most 
recent rendition.45 Higher intake of adequacy components per 1000 kcal resulted in a higher 
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HEI score. Adequacy components included total fruits, whole fruits, total vegetables, 
greens/beans, whole grains, milk/dairy, total protein foods, seafood/plant proteins, and 
polyunsaturated and monounsaturated fatty acids to saturated fatty acids ratio. Higher 
intake of moderation components resulted in a lower HEI score. Moderation components 
included saturated fats, refined grains, sodium, and added sugars.  
 
DATA AND STATISTICAL ANALYSES 
Baseline characteristics were compared using JMP 14.0.0(R) (SAS Institute, Cary, 
NC, USA). Wilcoxon rank sum test was used for non-normal parametric data, chi-square 
test was used for nominal data, and Fischer’s exact test was used when expected counts 
were less than five.  
 
Objective 1 
Alpha diversity was estimated with the Shannon index on raw OTU abundance 
tables after filtering out contaminants. The significance of diversity differences was tested 
using Wilcoxon rank sum. 
 
Objective 2 
Beta diversity was measured using Bray-Curtis indices and visualized using PCoA. 
OTUs were excluded if they occurred in fewer than 10% of samples with a count of less 
than 3. 
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Variation in community structure was assessed with permutational multivariate 
analyses of variance (PERMANOVA) with treatment group as the main fixed factor and 
using 4,999 permutations for significance testing. 
 
Objective 3 
Subject characteristic comparisons were calculated using the Wilcoxon rank sum 
test. The impact of age and obesity on beta diversity was evaluated using PERMANOVA. 
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Chapter Five: Results 
COHORT DESCRIPTION 
The study was comprised of 37 subjects, 14 with T2DM and 23 without diabetes. 
All subjects self-identified as Mexican American. The median age (IQR) was 59 years (48-
68), and 27 (73%) were female. Overall, participants were overweight, and about half 
(46%) had hypertension. Rates of other comorbidities can be found in Table 5. 
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Table 5: Baseline Characteristics 
Characteristic All subjects 
(N = 37) 
Diabetes 
(n = 14) 
No diabetes 
(n = 23) 
p-value 
Age, median (IQR), years 59 (48-68) 68 (59-72) 55 (38-61) 0.0032 
Female, no. (%) 27 (73) 9 (64) 18 (78) 0.4537 
BMI *, median (IQR), kg/m2 28.7 (26.6-34) 30 (26-36) 28 (27-31) 0.4653 
Metformin, no. (%) 12 (33) 12(86) 0 (0) £ 0.0001 
Sulfonylurea, no. (%) 3 (8) 3 (21) 0 (0) 0.0122 
GLP-1 RA, no. (%) 3 (8) 3 (21) 0 (0) 0.0122 
Insulin, no. (%) 2 (5) 2 (14) 0 (0) 0.0435 
HMG-CoA Reductase inhibitor+ 10 (28) 8 (57) 2 (9) 0.0016 
ACEI/ARB^ 11 (32) 8 (57) 3 (15) 0.0092 
Beta-blocker^ 5 (15) 3 (21) 2 (10) 0.3584 
Diuretic 2 (5) 0 (0) 2 (14) 0.0435 
Highest level of education, no. (%) 
High school or equivalent 
Some college, no degree 
Associate’s degree 
Bachelor’s degree 
Master’s degree 
 
8 (22) 
14 (38) 
6 (16) 
4 (11) 
1 (3) 
 
2 (14) 
8 (57) 
3 (21) 
0 (0) 
0(0) 
 
6 (26) 
6 (26) 
3 (13) 
4 (17) 
1 (4) 
0.2893 
Employment status, no (%) 
Retired 
Employed for wages 
Out of work/looking for work 
 
15 (41) 
17 (46) 
5 (14) 
 
11(79) 
1 (7) 
2 (14) 
 
4 (17) 
16 (70) 
3 (13) 
£ 0.0001 
Hypertension, no. (%) 17 (46) 9 (53) 5 (25) 0.0793 
Dyslipidemia, no. (%) 10 (27) 5 (36) 5 (22) 0.3574 
History of MI, no. (%) 1 (3) 1 (7) 0 (0) 0.3784 
History of cancer, no. (%) 1 (3) 1 (7) 0 (0) 0.3784 
Depression, no. (%) 1 (3) 1 (7) 0 (0) 0.3784 
IBS, no. (%) 1 (3) 0 (0) 1 (4) 1.0000 
HEI score, median (IQR) 53.5 (42.7-
66.6) 
62.0 (60.0-
65.8) 
48.5 (40.0-
68.4) 
0.2340 
Household income, dollars, median 
(IQR) 
24,000 (4,850-
55,000) 
25,500 (1,275-
56,250) 
24,000 (8,400-
60,000) 
0.7419 
Mexico birth, no. (%) 
Subjects 
Parents 
Grandparents 
 
3 (8) 
9 (24) 
22 (59) 
 
2 (14) 
3 (21) 
8 (57) 
 
1 (4) 
6 (26) 
14 (61) 
 
0.29 
0.7473 
0.8230 
IQR, interquartile range; BMI, body mass index; GLP-1 RA, glucagon-like peptide-1 
receptor agonist; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II 
receptor blocker;  MI, myocardial infarction; IBS, irritable bowel syndrome; HEI, healthy 
eating index scores  
*BMI not reported by one subject 
+One subject excluded for reporting “cholesterol medication” 
^Three subjects excluded for reporting “blood pressure medication” 
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Subjects with diabetes were older than those without diabetes (68 versus 55 years; 
p=0.0032). Rates of disease of the cardiovascular system (e.g. hypertension, dyslipidemia, 
and history of myocardial infarction [MI]) were not significantly different between groups; 
however, rates were numerically higher in those with T2DM. Twelve of the 14 subjects 
with diabetes (86%) took metformin.  
 
OBJECTIVE 1: ALPHA DIVERSITY 
There was no significant difference in Shannon diversity between subjects with and 
without T2DM, though subjects with T2DM had a slightly numerically lower alpha 
diversity (3.26 versus 3.31; p=0.341) (Figure 5). 
 
 
 
Figure 5: Shannon Diversity by Diabetes Status 
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OBJECTIVE 2: MICROBIAL COMPOSITION 
The most dominant phyla for both groups were Bacteroidetes (56% in T2DM, 51% 
in non-T2DM, p=0.17), followed by Firmicutes (32% in both groups), and Proteobacteria 
(4% in both groups) (Figure 6).  
 
 
Figure 6: Dominant Phyla 
 
The lower RA of Bacteroidetes resulted in a higher Firmicutes to Bacteroidetes 
ratio in subjects with T2DM (Table 6).  
 
Table 6: Firmicutes to Bacteroidetes Ratio 
 Diabetic Non-diabetic 
Firmicutes to Bacteroidetes ratio 0.637:1 0.507:1 
Firmicutes RA 32% 32% 
Bacteroidetes RA 51% 56% 
RA, relative abundance 
 
0%
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40%
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There was a significant difference in the RA of 16 OTUs between groups. Figure 7 
depicts the microbiome taxa differences by T2DM status and BMI category. 
 
 
 
Figure 7: Relative Abundance by Species 
 
When the RA of different genera were compared between groups, the proportion 
of Streptococcus was significantly higher in the subjects without T2DM (p=0.048). 
Additionally, subject 35 had a high RA of Blautia, as shown in Table 7. 
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Table 7: Blautia Median RA 
Group RA 
Subject 35 38% 
T2DM 0.7% 
Non-T2DM 0.7% 
 
OBJECTIVE 2: BETA DIVERSITY 
There were no significant differences in beta diversity between subjects with and 
without T2DM as measured by PERMANOVA (p = 0.20) (Figure 8).  
 
 
 
Figure 8: Microbiome Similarity 
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No strong associations are apparent by disease status; however, two distinct clusters 
are apparent in the lower left and lower right quadrants. Generally, there are more T2DM 
points on the left side of the PCoA. When HEI scores were calculated and assigned to each 
point, clustering was not significant (p=0.4962).  
The most distinct coordinate is subject 35, who is obese and has diabetes. This 
subject was the only subject taking a tricyclic antidepressant.  
 
OBJECTIVE 3: SUBJECT CHARACTERISTICS AND MICROBIAL DIVERSITY 
Beta diversity was not significantly different by age although there was a scatter of 
older individuals toward the top left of the PCoA (Figure 9).  
 
 
 
Figure 9: Microbiome Similarity by Age 
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Beta-diversity was not significantly different by BMI (Figure 10). However, there 
is a high degree of similarity between several high BMI subjects: 20, 25, and 30. 
 
 
 
Figure 10: Microbiome Similarity by BMI 
 
Furthermore, PCoA coordinates were not associated with HEI scores (p=0.49) or 
metformin use (p=0.7670). 
 
 
 
 28 
Chapter Six: Discussion 
OBJECTIVE 1 
Our study found no difference in alpha diversity between Mexican Americans with 
and without T2DM (Figure 5). As mentioned previously, no prior studies examined gut 
microbial composition difference between Hispanics with and without T2DM. One study 
included 15 (31%) Hispanic subjects, but the majority of subjects were white (57%).21 
However, this study’s findings agreed with our own in that alpha diversity was slightly, 
but not significantly, lower in prediabetic and T2DM subjects (5.26 and 5.21, respectively) 
compared to non-T2DM subjects (5.46).  
Although alpha diversity has been shown to be a marker of multiple diseases, 
including obesity46,47,  colorectal cancer33, and type 1 diabetes29, multiple gut microbiome 
studies in T2DM demonstrated that alpha diversity is not significantly different between 
subjects with and without T2DM.19,22 These studies have not provided rationale as to why 
there is no difference in alpha diversity. One study by Zhang, et al. determined that alpha 
diversity was negatively correlated with insulin resistance.24 It is unclear why alpha 
diversity results are so variable. Multiple factors can contribute to gut diversity, including 
diet and medications.48,49 Our study collected the data necessary to examine the influence 
of diet and medications on alpha diversity. For example, from subject food diaries, we 
calculated HEI scores. HEI scores are a validated method of quantifying diet quality that 
offers a less biased measurement than other methods, such as food-frequency 
questionnaires.50 HEI scores were not significantly different between groups, with a 
median of 62 in those with T2DM versus 48.5 in those without T2DM. Though not 
significantly different, subjects with T2DM had a numerically higher HEI score, indicating 
overall superior diet. It is difficult to interpret the clinical significance of this 13.5 point 
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difference in the context of our study because previous studies have used HEI scores for 
stratifying subjects, while our study treated HEI scores as a confounding variable. It is 
possible that differences in HEI contributed to greater than expected bacterial diversity in 
T2DM subjects. Interestingly, the national average HEI score is 59, which is closer to the 
scores of our T2DM subjects compared to those without T2DM.51  
Another major difference that could have contributed to lack of alpha diversity 
differences between groups is medication usage, specifically metformin, which is 
considered first-line therapy for T2DM according to the American Diabetes Association 
guidelines.52 Metformin has been shown to increase gut microbial diversity compared to 
subjects with T2DM not on metformin.53 The aforementioned studies did not report 
subjects’ medication usage; therefore, these studies were not able to determine whether 
metformin usage contributed to the lack of differences seen in alpha diversity between 
groups.19-24 Conversely, in our study 86% of subjects with T2DM took metformin 
compared to 0% in the non-T2DM subjects. This high rate of metformin use in those with 
T2DM could have led to increased alpha diversity in that group, resulting in similar alpha 
diversities between groups. 
 
OBJECTIVE 2 
The microbial composition was significantly different between groups. Most of the 
changes observed in this study did not support findings from previous studies (Table 8). 
For example, our study found no significant differences in the RA of Lactobacillus, 
Bacteroides, Prevotella, Clostidia, Bifidobacterium, or Roseburia. 
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Table 8: Microbial RA Compared to Other Studies 
References Microbiota in subjects 
with T2DM – other studies 
Microbiota in subjects 
with T2DM – our study 
Wu et al. (2010), Sedighi et al. 
(2017)  
¯ Bifidobacterium « Bifidobacterium 
Larsen et al. (2010), Lambeth et 
al. (2015) 
¯ Firmicutes « Firmicutes 
­ Firmicutes:Bacteroidetes 
ratio 
Larsen, et al. (2010), Qin et al. 
(2012), Karlsson et al. (2013) 
¯ Roseburia « Roseburia 
Larsen et al. (2010), Zhang et al 
(2013) 
­ Prevotella « Prevotella 
Wu et al. (2017) ¯ Prevotella 
Zhang et al. (2013) ¯ Bacteroides « Bacteroides 
Wu et al. ­ Bacteroides 
Larsen et al (2010), Wu et al. 
(2010), Qin et al. (2012), 
Karlsson et al. (2013), Sedighi et 
al. (2017) 
­ Lactobacillus 
 
« Lactobacillus 
Larsen et al. (2010) ¯ Clostridia « Clostridia 
Zhang et al. (2013) ­ Clostridia 
­, increase; ¯, decrease; «, no significant difference 
 
Our findings regarding the Firmicutes to Bacteroidetes ratio conflicts with findings 
from previous studies, including the study by Lambeth, et al., which included 15 (31%) 
Hispanic subjects.21 Lambeth, et al. found a lower RA of Firmicutes in subjects with T2DM 
(34.4%) compared to those without (39.7%), and Bacteroidetes RA was about the same in 
both groups (Table 9). This resulted in a lower Firmicutes to Bacteroidetes ratio in subjects 
with T2DM, which conflicts with our results. Of note, Bacteroidetes RA was the main 
driver of the Firmicutes to Bacteroidetes ratio in our study, whereas Firmicutes RA was 
the main driver in the study by Lambeth, et al. 
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Table 9: Firmicutes to Bacteroidetes Ratio in Previous Study 
 Our study Lambeth, et al. 
 Diabetic Non-
diabetic 
Diabetic Non-
diabetic 
Firmicutes to Bacteroidetes 
ratio 
0.637:1 0.507:1 0.64:1 0.74:1 
Firmicutes RA 32% 32% 34.4% 39.7% 
Bacteroidetes RA 56% 51% 53.9% 53.5% 
 
Increases in this ratio have been implicated in increased energy harvest and 
obesity.54 Though our subjects with and without T2DM did not have statistically different 
BMIs, the T2DM group had a numerically higher median BMI of 30, which is classified 
as obese. The non-T2DM group had a median BMI of 28, which is considered overweight. 
Thus, the increase in the Firmicutes to Bacteroidetes ratio may indicate that the ratio is 
more related to BMI and obesity as opposed to diabetes status. Another possible 
explanation is that the Firmicutes to Bacteroidetes ratio is related to T2DM control. 
Streptococcus genus had a significantly higher RA in non-T2DM subjects 
compared to subjects with T2DM. Streptococcus has been associated with atherosclerotic 
cardiovascular disease (ASCVD), hypertension, and enhanced thrombotic risk.55-57 It is 
therefore surprising that Streptococcus was enriched in our non-T2DM subjects as they 
had overall lower rates of cardiovascular-related diseases, and T2DM itself is a risk factor 
for cardiovascular disease. One possible explanation for this is the microbiome modulatory 
effects of metformin. The groups were similar except for diabetes status, and the majority 
of our diabetic subjects were on metformin. Metformin use could have resulted in a 
microbiome that is less like that of a person with ASCVD. In addition, differences in diet 
could have contributed to the observed difference in Streptococcus RA. 
Contrary to previous studies, there was no association between beta-diversity and 
T2DM status.20,22 This is likely because the control groups in previous studies were 
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healthier in general, whereas the non-T2DM subjects in our study had high rates of 
cardiovascular-related disease and a high median BMI, making their overall health more 
similar to the T2DM group. Furthermore, as mentioned previously, metformin 
demonstrates microbiome-modulating effects in T2DM.53 Those taking metformin have 
increases in butyrate-producing bacteria. Although our study did not show significantly 
higher RA of specific butyrate-producing species, such as Roseburia spp., we did observe 
an overall increase in Firmicutes, many of which are butyrate-producers.18  
The most visually distinct microbiome on the PCoA was that of subject 35, who 
was allowed into the study while taking a tricyclic antidepressant because there are 
currently no microbiome studies examining tricyclic antidepressants’ direct effects on the 
gut microbiome composition. When analyzed, subject 35’s gut microbiome demonstrated 
a high RA of Blautia. This subject was obese, so these findings are consistent with previous 
studies which demonstrated this genus’s association with high BMI.57,58 However, tricyclic 
antidepressant use may also play a role in this subject’s gut microbial composition. There 
is an established relationship between the gut and brain, referred to as the gut-brain axis, 
wherein the gut microbiota and the brain utilize bidirectional signaling to maintain 
homeostasis.59 Selective serotonin reuptake inhibitors (SSRIs), another class of 
serotonergic antidepressants, have been shown to impact gut microbiome composition.60 
There are currently no studies evaluating the effects of tricyclic antidepressants on the gut 
microbiome. Our findings suggests that tricyclic antidepressants, like SSRIs, may impact 
the gut microbiome composition. 
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OBJECTIVE 3 
Beta diversity was not significantly different between subjects when analyzed by 
subject age or BMI. This is surprising as prior studies have identified these to be major 
mediators of the gut microbiome. As noted previously, BMI had been associated with 
differences in the Firmicutes to Bacteroidetes ratio, and weight loss results in changes in 
microbial composition.61 Aging has been associated with decreased bacterial diversity, a 
decrease in SCFA-producing bacteria, and compositional differences that predispose hosts 
to pathogen invasion.62 The lack of significance seen in beta-diversity when compared by 
BMI and age indicates that microbial similarity between subjects is complicated and multi-
faceted. Our subjects’ baseline characteristics likely played a role in these results. Our 
subjects were well-matched with respect to comorbidities, BMI, and diet. 
One major difference between our study and previous studies is that we collected 
and reported a plethora of baseline and demographic characteristics. Previous studies rarely 
reported patient characteristics and demographic information, which limits the ability to 
interpret their results in the context of other comorbidities. Of the two studies that reported 
baseline data, the subjects were healthier overall, with lower BMIs and fewer comorbidities 
compared to those in our study.20,24  
The similar health status between our cohorts may also explain other discrepant 
findings. For example, as mentioned previously, contrary to previous findings, the T2DM 
group in our study had a higher RA of Firmicutes. This may indicate that the ratio is more 
related to BMI and obesity as opposed to diabetes status. 
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STRENGTHS 
This was the first study to compare the gut microbiome composition between 
diabetic and non-diabetic subjects in a completely Mexican American population. Mexican 
Americans have been underrepresented in gut microbiome studies of diabetes despite 
having higher diabetes prevalence compared to most other races and ethnicities.  
Additionally, we collected extensive background and health information, including 
medication use, height, weight, and comorbidities, which is helpful when interpreting study 
results, as all of those characteristics can influence and be influenced by the gut 
microbiome.  
Finally, we compared two well-matched groups; both groups had high median 
BMIs and similar rates of cardiovascular comorbidities. To date, most T2DM gut 
microbiome studies have compared healthier subjects with lower BMIs and no reported 
comorbidities. While this allowed investigators to focus on the relationship between the 
gut microbiome and diabetes alone, a relationship also exists between the gut microbiome 
and obesity and other comorbidities. Because the comparator group has these 
comorbidities, our study offers valuable insights into the kind of dysbiosis connected 
specifically to diabetes even when other comorbidities are present, as they often are in 
clinical practice.  
 
LIMITATIONS 
There are several limitations to the study which stem mostly from the fact that it 
was a small pilot study. For example, the study may not have been powered to detect the 
differences in microbial RA identified in previous studies. However, despite this small 
sample size, we were able to identify several novel differences between groups.  
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Another limitation was that all demographic and health information was self-
reported by the subjects. Up to one-third of all people with diabetes are not diagnosed, so 
it is possible that some of our non-diabetic subjects had diabetes. Furthermore, comorbid 
diseases, height, weight, and medications might have been inaccurately reported. 
Finally, we could not control for all microbiome mediators. Although we were able 
to show that the groups were well-matched with respect to diet, comorbidities, and BMI, 
there are too many mediators of the microbiome to be able to account for them all.  
 
CONCLUSIONS AND FUTURE RESEARCH 
Alpha and beta diversity were not significantly different between diabetic and non-
diabetic Mexican American subjects; however, microbial composition was significantly 
different between groups.  
The results of this study offer valuable insight into how scientists can target the gut 
microbiome of individuals who have T2DM and other comorbidities. Additionally, having 
knowledge of how the gut microbiomes of Mexican Americans differ from those examined 
in previous studies will allow researchers to more accurately target individuals’ gut 
microbiomes to prevent or treat T2DM.  
Further, several interesting findings from this study could stimulate further 
research. For example, the high RA of Streptococcus in non-diabetic subjects with lower 
rates of diseases that predispose one to atherosclerotic cardiovascular disease warrants 
further investigation. Also, tricyclic antidepressant effects on the gut microbiome is another 
area thus unstudied that could be examined. Finally, it is possible that metformin modulates 
multiple facets of metabolic health through its effects on the gut microbiome. Comparative 
studies are needed to examine the gut microbiome pre- and post-metformin initiation. 
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The next step in the analysis of this data set is to compare it to HMP data to 
determine the impact of Mexican American ethnicity on the gut microbiome. 
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Appendix: Data Collection Sheet 
Age:  Height:  Weight:  Sex: 
Country of birth (please circle one for each: 
Self: United States    Parents:  United States Grandparents: United Sates 
Mexico          Mexico         Mexico  
Other           Other       Other 
Highest level of education completed (please circle one): 
No schooling 
Some high school, no diploma 
High school graduate or 
equivalent (ex. GED) 
Trade/technical/vocational 
training 
Some college, no degree 
Associate degree 
Bachelor’s degree 
Master’s degree 
Doctorate degree (ex. PhD, MD, 
PharmD) 
Approximate household income: $ ___________ 
Current employment status (circle one): 
Employed for wages 
Out of work and looking for 
work 
Out of work but not currently 
looking for work 
Homemaker 
Military 
Student 
Retired 
Unable to work 
Social History: 
Do you use either of the following in any quantity (please circle no or yes)? 
Tobacco No  Yes Approximate quantity per week: 
Alcohol No Yes Approximate quantity per week: 
 
 
Medical History:  
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Please circle any medical condition you currently have or have a history of: 
High blood pressure 
High cholesterol 
Heart attack 
Heart failure 
Vascular disease 
Stroke 
Diabetes 
Kidney disease 
Cancer 
HIV or AIDS 
Anxiety 
Depression 
Dementia 
COPD 
Peptic ulcer disease 
Liver disease 
Inflammatory bowel 
disease 
Irritable bowel syndrome 
Please list all other chronic medical conditions: 
 
 
Medication History: 
Please list all medications, including prescription, over-the-counter, and herbal 
medications used daily or in the past 2 months: 
 
 
 
 
** For participants with diabetes ** 
Approximate time since first diabetes diagnosis (if known): _________ 
Last hemoglobin A1c value (if known): _________ 
Last fasting glucose value (if known): ________ 
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Glossary 
 
ASCVD Atherosclerotic cardiovascular disease 
BMI Body mass index 
FORU First Outpatient Research Unit 
GLP-1 Glucagon-like peptide 1 
GPCR G-protein coupled receptor 
HEI Healthy Eating Index 
IBD Inflammatory bowel disease 
IBS Irritable bowel syndrome 
LPS Lipopolysaccharide 
MARC Medical Arts and Research Center 
OTU Operational taxonomic unit 
PCoA Principle coordinate analysis 
PCR Polymerase chain reaction 
RA Relative abundance 
rRNA Ribosomal ribonucleic acid 
SCFA Short-chain fatty acids 
SSRI Selective serotonin reuptake inhibitor 
T2DM Type 2 diabetes mellitus 
TLR4 Toll-like receptor-4 
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